Subcutaneous Insulin
Sponsors
Pfizer, Kathleen Dungan, Benha University, Sam Chun Dang Pharm. Co. Ltd.
Conditions
AsthmaCOVID-19Chronic Obstructive Pulmonary DiseaseCongestive Heart FailureDiabetes MellitusDiabetes Mellitus, Type 1DysglycemiaInpatient
Phase 1
Glycemic Control and Variability for Congestive Heart Failure Exacerbation
CompletedNCT00812487
Start: 2009-01-31End: 2013-09-30Updated: 2013-12-31
Can Intensive Insulin Therapy Improve Outcomes of COVID-19 Patients
CompletedNCT05441631
Start: 2020-04-01End: 2021-12-01Updated: 2024-08-01
Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
RecruitingNCT07634770
Start: 2026-05-29End: 2026-10-01Target: 16Updated: 2026-06-09
Phase 2
Phase 3
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes
TerminatedNCT00137046
Start: 2002-05-31End: 2008-12-31Updated: 2010-02-18
Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 2 Diabetes
TerminatedNCT00136916
Start: 2002-06-30End: 2008-12-31Updated: 2010-02-18
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With COPD
TerminatedNCT00138671
Start: 2003-01-31End: 2008-09-30Updated: 2010-02-02
A One Year Clinical Trial Assessing the Usefulness and Safety of Inhaled Insulin in Diabetics With Asthma
CompletedNCT00139659
Start: 2003-01-31End: 2008-10-31Updated: 2010-06-02